How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
The good news about donanemab, Eli Lilly’s Alzheimer’s drug, reached CEO Dave Ricks on July 2 as he was hiking in a remote part of Colorado. The pharmaceutical company had slogged for 35 years and spent $8 billion to develop an effective treatment for the …